Cap-dependent endonuclease inhibitors (CENis) - NHRC
Closed Solicitation Posted
- Solicitation number
- N0018926QB059
- Agency
-
Naval Supply Systems Command
Department of the Navy, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- Galveston, Texas, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Naval Medical Research Center seeks preclinical development of cap-dependent endonuclease inhibitors (CENis) as broad-spectrum antiviral therapeutics, with proposals due May 28, 2026. The procurement is set aside for women-owned small businesses and is structured as a firm fixed price request for quote.
Work is performed at the University of Texas Medical Branch in Galveston, Texas over a 36-month period (May 29, 2026 to May 28, 2029), with deliverable acceptance at the Naval Medical Research Center in Silver Spring, Maryland. The scope encompasses in vitro and in vivo efficacy studies, lead candidate selection and characterization, and optimization of compounds, including work with viruses requiring biosafety level 4 containment. The solicitation includes two cost line items: Labor (CLIN 0001) on a firm fixed price basis and Other Direct Costs (CLIN 0002) on a cost-no-fee basis. Key deliverables include a project management plan, in vitro screening assays, IACUC and OHARO approvals, and comprehensive efficacy study reports. The Principal Investigator is Dr. Slobodan Paessler. The NAICS code is 541715, Research and Development in the Physical, Engineering, and Life Sciences; PSC is AN42, Health R&D Services. Payment is processed through the Wide Area WorkFlow system.
Notice text
The preclinical development of Cap-dependent endonuclease inhibitors (CENi), a class of small molecules, as broad-spectrum antiviral therapeutics. The scope of this project includes all activities required to select lead CENi candidates, including in vitro and in vivo efficacy studies and characterization and optimization of lead compounds. This includes Research Support expertise regarding the preclinical development of cap-dependent endonuclease inhibitors (CENis) with viruses that require biosafety level 4 (BSL-4) containment to support the Naval Medical Research Command in Fort Detrick, MD. This work will be performed over a 36-month period.
Files
| File | Type | Posted |
|---|---|---|
| Solicitation Amendment - N0018926QB0590001.pdf | ||
| Solicitation - N0018926QB059.pdf | ||
| PWS CENi_RFQ.pdf | ||
| Combined Synopsis.pdf |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity